LABORATORY OF PRECLINICAL TESTING OF HIGHER STANDARD

Head: Urszula Wojda

 

Degrees:
2013 Professor of Biological Sciences, nomination by President of the Republic of Poland
2004 DSc Habil, Nencki Institute of Experimental Biology, PAS
1996 PhD in Biochemistry, Nencki Institute of Experimental Biology, PAS
2010 Postgraduate Diploma in Management, Warsaw Medical University/ Warsaw School of Economics
1987 MSc in Molecular Biology, Faculty of Biology, University of Warsaw

 

Research trainings:
1996-2001 Postdoc, Bioorganic Chemistry Lab., NIDDK, National Institutes of Health, USA
1991 Visiting PhD student, Department of Biophysics, Pasteur University, Strasbourg, France

 

Professional employments:
2015-present Head of the Laboratory of Preclinical Studies of Higher Standard, Nencki Institute of Experimental Biology, PAS
2002-2012 Associated Professor, Deputy Head, Lab. of Neurodegeneration, International Institute of Molecular and Cell Biology, Warsaw

 

Honors and fellowships:

2017 EU Horizon2020 Novel Ideas for Radically New Technologies FETOPEN GRANT
2015-present Member of the Management Board of the Polish Biochemical Society
2014 President  of  the  international  conference BIO2014 in Warsaw (900 participants)
2013-present Polish expert in the Management Board of EU JPND, the largest international organization for funding research in neurodegeneration Fellowships: Fogarty International Center, FEBS Member of the Editorial Boards: Journal of Alzheimer’s disease, Journal of Applied Genetics

Staff: Małgorzata Cira, Marek Gryzik, Iga Lachowicz, Katarzyna Laskowska-Kaszub (PhD student), Siranjeevi Nagaraj (PhD student), Anna Mietelska-Porowska, Anna Piotrowska, Angelika Więckowska (PhD student), Joanna Wojsiat (PhD student), Małgorzata Wydrych, Katarzyna Żółtowska

 


Research profile:

Core facility with its own research program launched in 2014 at the Nencki Neurobiology Center within the framework of the Centre for Preclinical Research and Technology (CePT). The laboratory conducts its own basic research on the early molecular mechanisms of neurodegenerative diseases aiming at identifying novel drug targets and biomarkers.

As a core facility, the laboratory performs comprehensive preclinical tests of potential new therapeutic strategies for diseases of the nervous system, as well as cancer, for internal and external customers or collaborating partners (research institutes, biotech and pharma companies) from Poland and from abroad. The laboratory consists of a group of stations with modern apparatus that enables preclinical tests in cell cultures in vitro and in animal models in vivo in accordance with the principles of Good Laboratory Practice (GLP) and a higher standard.

 


Current research activities:

• Search for blood-based early biomarkers of Alzheimer’s disease (AD) by identifying systemic molecular changes in progression of the pathology:  profiling microRNAs and proteins in blood cells and blood plasma from AD patients.

• Investigating the role of oxidative stress, aberrant cell cycle regulation and apoptosis in AD pathogenesis; focus on the involvement of the p53-p21 signaling pathway

• Analysis of the involvement of familial Alzheimer’s disease associated mutated Presenilin1 in cellular responses to oxidative stress

• Developing cellular models of Alzheimer’s disease: in vitro cultures of fibroblasts and lymphocytes from AD patients and of human AD neurons derived from reprogrammed fibroblasts

• Developing novel mouse models of sporadic Alzheimer’s disease

• Correlation study of AD biomarkers in human blood and in the blood of AD mouse models (model validation)

• Disorders of Ca2+ signaling proteins in AD

• Preclinical evaluation of novel potential anticancer therapeutics: mechanisms of cellular activity, pharmacokinetics, activity in mouse xenotransplantation cancer models.

 

UE Horizon 2020 FETOPEN grant at the Nencki Institute

 

Prof. Urszula Wojda is a member of an international consortium that has received a EU Horizon 2020 grant in the FETOPEN: Research & Innovation Action, Novel Ideas for Radically New Technologies competition. The aim of the consortium’s research is to develop new strategies for the treatment and diagnosis of Alzheimer's disease based on studies of glycobiological alterations in AD. The “ArrestAD” project received the highest possible evaluation of reviewers (15/15).

The consortium of the "ArrestAD" project includes the following entities:

Consortium leader: University of Paris Est Créteil FR

  • THE UNIVERSITY OF LIVERPOOL UK
  • STICHTING KATHOLIEKE UNIVERSITEIT NL
  • INSTYTUT BIOLOGII DOSWIADCZALNEJ IM. M. NENCKIEGO POLSKIEJ AKADEMII NAUK PL
  • FUNDACION DE INVESTIGACION DEL CANCER DE LA UNIVERSIDAD DE SALAMANCA ES
  • ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS FR
  • UNIVERSITAT AUTONOMA DE BARCELONA ES 
  • SCREENCELL Company


Prof. Urszula Wojda with her group from the Laboratory of Preclinical Studies of Higher Standard of the Neurobiology Centre at the Nencki Institute examines the relationships between genetic and proteomic factors of AD and changes of glycosaminoglycans in blood cells, as a basis for developing new strategies for the early diagnosis of AD. Blood samples for the research are provided by Prof. Thomas Gabryelewicz’s team from the Alzheimer’s Ward of the Central Clinical Hospital of the Ministry of the Interior and Administration in Warsaw.

 

http://cordis.europa.eu/project/rcn/207479_en.html

 

 

Selected publications:

 

Nagaraj S., Laskowska-Kaszub K., Dębski K.J., Wojsiat J., Dąbrowski M., Gabryelewicz T., Kuźnicki J., Wojda U. (2017) Profile of 6 microRNA in blood plasma distinguish early stage Alzheimer's disease patients from non-demented subjects. Oncotarget, doi: 10.18632/oncotarget.15109. The article featured on the cover for issue 10 (Vol 8).

 

Mietelska-Porowska A., Wojda U. (2017) T Lymphocytes and Inflammatory Mediators in the Interplay between Brain and Blood in Alzheimer’s Disease: Potential Pools of New Biomarkers. Journal Immunology Research, ID 4626540, https://doi.org/10.1155/2017/4626540.

 

Wojsiat J., Laskowska-Kaszub K., Alquézar C., Białopiotrowicz E., Esteras N., Zdioruk M., Martin-Requero A., Wojda U. (2016) Familial Alzheimer's Disease Lymphocytes Respond Differently Than Sporadic Cells to Oxidative Stress: Upregulated p53-p21 Signaling Linked with Presenilin 1 Mutants. Mol Neurobiol, doi:10.1007/s12035-016-0105-y.

 

Wojda U. (2016) Alzheimer's Disease lymphocytes: potential for biomarkers? Biomark Med. 10(1):1-4.

 

Wojsiat J., Prandelli C., Laskowska-Kaszub K., Martín-Requero A., Wojda U. (2015) Oxidative stress and aberrant cell cycle in Alzheimer's disease lymphocytes: diagnostic prospects. J Alzheimers Dis, 46(2):329-50.